Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,359 | 457 | 96.4% |
| Education | $201.95 | 5 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $494.22 | 52 | $0 (2024) |
| Amgen Inc. | $467.99 | 32 | $0 (2024) |
| Lilly USA, LLC | $466.73 | 35 | $0 (2024) |
| Allergan, Inc. | $440.06 | 48 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $387.84 | 13 | $0 (2024) |
| Novo Nordisk Inc | $384.27 | 27 | $0 (2024) |
| Astellas Pharma US Inc | $346.47 | 32 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $283.39 | 31 | $0 (2021) |
| ABBVIE INC. | $272.55 | 18 | $0 (2024) |
| PFIZER INC. | $215.11 | 27 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $459.86 | 29 | ABBVIE INC. ($135.43) |
| 2023 | $443.48 | 28 | AbbVie Inc. ($96.38) |
| 2022 | $398.88 | 27 | Novo Nordisk Inc ($94.22) |
| 2021 | $477.45 | 33 | Janssen Pharmaceuticals, Inc ($134.67) |
| 2020 | $571.48 | 39 | AstraZeneca Pharmaceuticals LP ($116.48) |
| 2019 | $1,005 | 95 | Merck Sharp & Dohme Corporation ($195.09) |
| 2018 | $1,219 | 108 | Allergan Inc. ($186.06) |
| 2017 | $986.70 | 103 | Allergan Inc. ($201.27) |
All Payment Transactions
462 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: NEUROSCIENCE | ||||||
| 10/14/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $19.16 | General |
| Category: Bone Health | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Respiratory | ||||||
| 09/25/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: Biological | ||||||
| 09/09/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Obesity | ||||||
| 08/31/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/27/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: PAIN | ||||||
| 08/19/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Diabetes | ||||||
| 08/14/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.48 | General |
| Category: NEUROSCIENCE | ||||||
| 08/09/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.02 | General |
| Category: Cardiovascular | ||||||
| 07/23/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Biological | ||||||
| 07/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: NEUROSCIENCE | ||||||
| 05/31/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/13/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), VAXNEUVANCE, GARDASIL 9 | Food and Beverage | In-kind items and services | $13.29 | General |
| Category: VACCINE | ||||||
| 05/04/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: Diabetes | ||||||
| 04/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: NEUROSCIENCE | ||||||
| 04/17/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: Biological | ||||||
| 04/13/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: NEUROSCIENCE | ||||||
| 04/01/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.64 | General |
| Category: Inflammation | ||||||
| 03/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: NEUROSCIENCE | ||||||
| 03/09/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: Iron Deficiency Anemia | ||||||
| 02/29/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/16/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: NEUROSCIENCE | ||||||
| 02/02/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: Diabetes | ||||||
| 01/27/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 492 | 762 | $86,797 | $40,141 |
| 2022 | 5 | 545 | 809 | $91,211 | $43,583 |
| 2021 | 5 | 624 | 929 | $96,369 | $51,176 |
| 2020 | 6 | 592 | 898 | $75,675 | $38,813 |
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 354 | 577 | $69,817 | $31,707 | 45.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 114 | 160 | $13,120 | $6,797 | 51.8% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 11 | 11 | $1,914 | $1,098 | 57.4% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 13 | 14 | $1,946 | $538.85 | 27.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 359 | 575 | $69,575 | $32,931 | 47.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 137 | 184 | $15,088 | $7,387 | 49.0% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 23 | 23 | $4,002 | $2,601 | 65.0% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2022 | 13 | 14 | $1,922 | $592.32 | 30.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2022 | 13 | 13 | $624.00 | $71.58 | 11.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 401 | 643 | $71,939 | $37,832 | 52.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 161 | 216 | $16,050 | $8,930 | 55.6% |
| 99495 | Transitional care management services, moderately complexity, requiring face-to-face visits within 14 days of discharge | Office | 2021 | 25 | 30 | $4,612 | $3,443 | 74.6% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2021 | 18 | 21 | $2,856 | $891.24 | 31.2% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Office | 2021 | 19 | 19 | $912.00 | $79.44 | 8.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 381 | 595 | $53,259 | $26,523 | 49.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 140 | 222 | $12,876 | $6,850 | 53.2% |
| 99495 | Transitional care management services, moderately complexity, requiring face-to-face visits within 14 days of discharge | Office | 2020 | 23 | 28 | $3,784 | $2,779 | 73.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 22 | 24 | $3,044 | $1,942 | 63.8% |
| G0180 | Physician certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implem | Office | 2020 | 12 | 15 | $2,040 | $642.61 | 31.5% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Office | 2020 | 14 | 14 | $672.00 | $74.93 | 11.2% |
About Dr. Dustin Snelling, MD
Dr. Dustin Snelling, MD is a Family Medicine healthcare provider based in Sioux Falls, South Dakota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174501043.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dustin Snelling, MD has received a total of $5,561 in payments from pharmaceutical and medical device companies, with $459.86 received in 2024. These payments were reported across 462 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($5,359).
As a Medicare-enrolled provider, Snelling has provided services to 2,253 Medicare beneficiaries, totaling 3,398 services with total Medicare billing of $173,712. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Sioux Falls, SD
- Active Since 01/02/2006
- Last Updated 11/14/2019
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1174501043
Products in Payments
- JANUVIA (Drug) $313.13
- VIBERZI (Drug) $219.30
- XARELTO (Drug) $213.17
- Ozempic (Drug) $196.72
- EVENITY (Biological) $160.68
- JARDIANCE (Drug) $156.51
- LONHALA MAGNAIR (Drug) $153.50
- FARXIGA (Drug) $152.31
- VRAYLAR (Drug) $144.34
- TRADJENTA (Drug) $140.79
- TRULICITY (Drug) $135.91
- Aimovig (Biological) $114.98
- MOUNJARO (Drug) $111.90
- Prolia (Biological) $111.67
- TOUJEO (Drug) $111.32
- SYMBICORT (Drug) $109.23
- LINZESS (Drug) $103.68
- Movantik (Drug) $99.88
- UBRELVY (Drug) $95.67
- BEVESPI AEROSPHERE (Drug) $95.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Sioux Falls
Dr. Elizabeth Jensen, Do, DO
Family Medicine — Payments: $23,645
Dr. Andrew Burchett, D.o, D.O
Family Medicine — Payments: $16,792
Lornell Hansen, Md, MD
Family Medicine — Payments: $11,056
Jeffry Meyer, Md, MD
Family Medicine — Payments: $8,449
Scott Boyens, Md, MD
Family Medicine — Payments: $6,526
William Buchner, Md, MD
Family Medicine — Payments: $5,715